Inclusion Criteria

• Documented informed consent from legal guardian.
• 0-84 days postnatal age at time of first study dose or when enrolled into the non-intervention cohort.
• Clinical diagnosis of superficial cutaneous or mucosal infantile hemangioma: (must include all of the following):
  • Superficial lesion in the dermis of the skin;
  • Thin (<2 mm in thickness);
  • ≥0.5cm at its longest dimension and ≤10 cm2;
  • Involves skin or keratinized mucosa.

Exclusion Criteria

• History of previous treatment with any pharmacologic or laser therapy for IH.
• Ongoing therapy with an oral beta blocker or oral corticosteroid (e.g., cardiac arrhythmia, adrenal insufficiency, upper airway obstruction, tetralogy of fallot, hypertension, reactive airways disease).
• IH that requires systemic therapy (defined by dynamic complication scale >3).
• Infants with more than one hemangioma that requires therapy.
• IH of the non-keratinized mucosa.
• Hemodynamically significant cardiovascular disease, as determined by the investigator.
• Known allergy to beta blockers or vehicle.
• Heart rate <100 beats per minute at screening visit.
• Known prenatal or postnatal diagnosis of 2nd/3rd degree atrioventricular block.
• History of reactive airway disease (RAD).
• Any condition which would make the participant, in the opinion of the investigator, unsuitable for the study.